HC Wainwright Cuts Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at HC Wainwright dropped their Q4 2025 EPS estimates for shares of TG Therapeutics in a note issued to investors on Monday, November 3rd. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings of $0.20 per share for the quarter, down from their previous estimate of $0.23. HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q1 2026 earnings at $0.23 EPS, Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at $0.32 EPS, Q4 2026 earnings at $0.51 EPS, FY2027 earnings at $1.95 EPS, FY2028 earnings at $2.41 EPS and FY2029 earnings at $3.05 EPS.

Several other research firms have also weighed in on TGTX. The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 price objective for the company in a research note on Thursday, July 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of TG Therapeutics in a research note on Wednesday, October 8th. B. Riley lifted their price target on shares of TG Therapeutics from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Finally, JPMorgan Chase & Co. boosted their price target on shares of TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research report on Monday. Three investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $50.25.

TG Therapeutics Stock Up 0.4%

Shares of NASDAQ TGTX opened at $33.81 on Tuesday. The company has a market capitalization of $5.36 billion, a P/E ratio of 91.38 and a beta of 1.97. TG Therapeutics has a 52-week low of $23.60 and a 52-week high of $46.48. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The company’s 50 day moving average price is $33.66 and its 200-day moving average price is $34.75.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $2.19. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company had revenue of $161.71 million for the quarter, compared to analyst estimates of $152.12 million. During the same period in the previous year, the firm posted $0.02 EPS. The firm’s revenue was up 92.7% on a year-over-year basis. TG Therapeutics has set its FY 2025 guidance at EPS.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares of the company’s stock, valued at $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 10.64% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its holdings in shares of TG Therapeutics by 54.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company’s stock valued at $898,000 after buying an additional 8,338 shares during the last quarter. New York State Teachers Retirement System grew its holdings in shares of TG Therapeutics by 175.0% during the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company’s stock valued at $4,746,000 after buying an additional 76,600 shares during the last quarter. Crossmark Global Holdings Inc. purchased a new stake in shares of TG Therapeutics during the first quarter valued at approximately $226,000. Strs Ohio purchased a new stake in shares of TG Therapeutics during the first quarter valued at approximately $785,000. Finally, KLP Kapitalforvaltning AS lifted its stake in TG Therapeutics by 7.7% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 30,800 shares of the biopharmaceutical company’s stock valued at $1,108,000 after acquiring an additional 2,200 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.